FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2559348532> ?p ?o ?g. }

• W2559348532 abstract "Abstract Abstract 4934 Multiple myeloma (MM) patients presenting with renal feature at disease onset should not be excluded from high-dose therapy programs; seeking novel effective and non-nephrotoxic induction regimens is thus mandatory in order to maximize the reduction of tumor burden prior to transplant. From May 2002 to February 2008, 31 newly diagnosed MM patients (18 male, 13 female, median age 60 years) with symptomatic MM and renal failure, defined as creatinine clearance '50ml/min, were enrolled in a clinical trial aimed at evaluating the efficacy and the feasibility of a thalidomide-based regimen as induction therapy in preparation to autologous stem cell transplantation. Sixteen patients had a more severe renal impairment (creatinine clearance '30ml/min) and 7 of them were in chronic hemodyalisis. After informed consent, patients received four months of combined oral thalidomide (thal) (100mg/day for two weeks and 200mg/day thereafter) and dexamethasone (dex) (40mg/day on day 1-4, 9-11, 17-20/28 days on odd cycles and on day 1-4 on even cycles); peripheral blood stem cell collection was thus to be performed after priming with high-dose cyclophosphamide + G-CSF or G-CSF alone; a single or double autologous stem cell transplantation was then to follow, upon preparation with high-dose melphalan. After induction, a PR or better was obtained in 23 patients (74%), with 8 patients (26%) achieving a VGPR or better. No difference in response rate was observed in patients with a baseline creatinine clearance ≥30ml/min (86%) or < 30ml/min (62%). An improvement in renal function was more frequently observed in patients achieving ≥ PR (82% vs. 37% in patients obtaining < PR, p =0.04). Twenty-six patients underwent peripheral blood stem cell mobilization; in 17 of them (65%) the procedure was successful resulting in the collection of > 4 × 106 CD34+ cells/kg. Fifteen patients received a double autologous stem cell transplantation while a single transplant was performed in four patients. Overall, median event-free survival was 30 months, and median survival has not been reached, upon 32 months median follow-up. Toxicity profile of thal-dex was comparable to that observed in patients with a normal renal function. In conclusion, our data show that thal-dex can be safely administered in patients with newly diagnosed MM and renal failure. given the relationship between recovery of renal function and response to induction treatment, more intensive thal + bortezomib-including regimens could be potentially useful in order to rescue a higher number of patients. Disclosures Off Label Use: Thalidomide plus dexamethasone in newly diagnosed multiple myeloma." @default.
• W2559348532 created "2016-12-08" @default.
• W2559348532 creator A5016860333 @default.
• W2559348532 creator A5024215041 @default.
• W2559348532 creator A5030245472 @default.
• W2559348532 creator A5040474758 @default.
• W2559348532 creator A5044224344 @default.
• W2559348532 creator A5051368482 @default.
• W2559348532 creator A5055543156 @default.
• W2559348532 creator A5056548877 @default.
• W2559348532 creator A5071926851 @default.
• W2559348532 creator A5088055048 @default.
• W2559348532 date "2009-11-20" @default.
• W2559348532 modified "2023-09-29" @default.
• W2559348532 title "Thalidomide-Dexamethasone as Induction Therapy Prior to Autologous Stem-Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma and Renal Failure." @default.
• W2559348532 doi "https://doi.org/10.1182/blood.v114.22.4934.4934" @default.
• W2559348532 hasPublicationYear "2009" @default.
• W2559348532 type Work @default.
• W2559348532 sameAs 2559348532 @default.
• W2559348532 citedByCount "0" @default.
• W2559348532 crossrefType "journal-article" @default.
• W2559348532 hasAuthorship W2559348532A5016860333 @default.
• W2559348532 hasAuthorship W2559348532A5024215041 @default.
• W2559348532 hasAuthorship W2559348532A5030245472 @default.
• W2559348532 hasAuthorship W2559348532A5040474758 @default.
• W2559348532 hasAuthorship W2559348532A5044224344 @default.
• W2559348532 hasAuthorship W2559348532A5051368482 @default.
• W2559348532 hasAuthorship W2559348532A5055543156 @default.
• W2559348532 hasAuthorship W2559348532A5056548877 @default.
• W2559348532 hasAuthorship W2559348532A5071926851 @default.
• W2559348532 hasAuthorship W2559348532A5088055048 @default.
• W2559348532 hasConcept C126322002 @default.
• W2559348532 hasConcept C126894567 @default.
• W2559348532 hasConcept C141071460 @default.
• W2559348532 hasConcept C159641895 @default.
• W2559348532 hasConcept C2776364478 @default.
• W2559348532 hasConcept C2777408962 @default.
• W2559348532 hasConcept C2778684742 @default.
• W2559348532 hasConcept C2779050716 @default.
• W2559348532 hasConcept C2779609412 @default.
• W2559348532 hasConcept C2780306776 @default.
• W2559348532 hasConcept C2780401358 @default.
• W2559348532 hasConcept C2911091166 @default.
• W2559348532 hasConcept C71924100 @default.
• W2559348532 hasConcept C90924648 @default.
• W2559348532 hasConceptScore W2559348532C126322002 @default.
• W2559348532 hasConceptScore W2559348532C126894567 @default.
• W2559348532 hasConceptScore W2559348532C141071460 @default.
• W2559348532 hasConceptScore W2559348532C159641895 @default.
• W2559348532 hasConceptScore W2559348532C2776364478 @default.
• W2559348532 hasConceptScore W2559348532C2777408962 @default.
• W2559348532 hasConceptScore W2559348532C2778684742 @default.
• W2559348532 hasConceptScore W2559348532C2779050716 @default.
• W2559348532 hasConceptScore W2559348532C2779609412 @default.
• W2559348532 hasConceptScore W2559348532C2780306776 @default.
• W2559348532 hasConceptScore W2559348532C2780401358 @default.
• W2559348532 hasConceptScore W2559348532C2911091166 @default.
• W2559348532 hasConceptScore W2559348532C71924100 @default.
• W2559348532 hasConceptScore W2559348532C90924648 @default.
• W2559348532 hasLocation W25593485321 @default.
• W2559348532 hasOpenAccess W2559348532 @default.
• W2559348532 hasPrimaryLocation W25593485321 @default.
• W2559348532 hasRelatedWork W1977668253 @default.
• W2559348532 hasRelatedWork W1992528163 @default.
• W2559348532 hasRelatedWork W2018183654 @default.
• W2559348532 hasRelatedWork W2228406254 @default.
• W2559348532 hasRelatedWork W2259033287 @default.
• W2559348532 hasRelatedWork W2407724235 @default.
• W2559348532 hasRelatedWork W2414440062 @default.
• W2559348532 hasRelatedWork W2554877131 @default.
• W2559348532 hasRelatedWork W2558147268 @default.
• W2559348532 hasRelatedWork W2567388251 @default.
• W2559348532 hasRelatedWork W2574893977 @default.
• W2559348532 hasRelatedWork W2575612264 @default.
• W2559348532 hasRelatedWork W2582903334 @default.
• W2559348532 hasRelatedWork W2588747205 @default.
• W2559348532 hasRelatedWork W2592256330 @default.
• W2559348532 hasRelatedWork W2970801600 @default.
• W2559348532 hasRelatedWork W2979550984 @default.
• W2559348532 hasRelatedWork W2992323073 @default.
• W2559348532 hasRelatedWork W2740029580 @default.
• W2559348532 hasRelatedWork W2741121800 @default.
• W2559348532 isParatext "false" @default.
• W2559348532 isRetracted "false" @default.
• W2559348532 magId "2559348532" @default.
• W2559348532 workType "article" @default.